ARTICLE | Company News
AnGes, BioLeaders deal
April 16, 2012 7:00 AM UTC
The companies partnered to develop an oral DNA vaccine to treat hypertension. The vaccine will target the angiotensin II type 1 (AT1) receptor (AGTR1) and the AT2 receptor. It uses DNA vaccine techno...